Literature DB >> 25907724

[Analysis on morbidity and mortality of viral hepatitis in China, 2004-2013].

Minna Zhang1, Yue Yuan2, Panyong Mao3, Yingjie Zhuang4.   

Abstract

OBJECTIVE: To understand the incidence and death patterns of viral hepatitis in China and provide evidence for the prevention and control of viral hepatitis.
METHODS: The analysis was conducted on the incidence and death data of viral hepatitis published by National Health and Family Planning Commission during 2004-2013.
RESULTS: The incidences of viral hepatitis in Guizhou,Yunnan, Tibet, Gansu, Qinghai,Ningxia and Xinjiang provinces (autonomous region) were high. The major forms were hepatitis B (80.63/100 000) and hepatitis C (9.68/100 000), accounting for 80.90% and 9.25% of the total reported viral hepatitis cases respectively. The incidences of hepatitis A and unidentified hepatitis decreased and the incidence of hepatitis B, C and E increased during this period. During the 10 years, 10 008 deaths caused by viral hepatitis were reported (1 001 deaths per year). The reported deaths caused by hepatitis A, hepatitis E and unidentified hepatitis decreased during this period. The reported deaths caused by hepatitis B were in a downward trend, but the constituent in total cases remained high. The reported deaths caused by hepatitis C were in an upward trend.
CONCLUSION: During 2004-2013, the overall incidence of viral hepatitis showed no downward trend in China. The incidence of hepatitis B remained high, and the incidence of hepatitis C showed an obvious upward trend. The overall death rate and case fatality rate of viral hepatitis showed a downward trend, but hepatitis B remained the main cause of viral hepatitis related death, and the death caused by hepatitis C was in increase. Hepatitis B and hepatitis C are the major targets in the prevention and treatment of viral hepatitis in China, and the 7 western provinces (autonomous region) with high incidences are the key regions of the prevention and control.

Entities:  

Mesh:

Year:  2015        PMID: 25907724

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  7 in total

1.  Socioeconomic inequality in Hepatitis B vaccination of rural adults in China.

Authors:  Dawei Zhu; Na Guo; Jian Wang; Stephen Nicholas; Zhen Wang; Guojie Zhang; Luwen Shi; Knut Reidar Wangen
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

2.  Regional differences of hepatitis B discrimination in rural China.

Authors:  Jun Li; Jian Wang; Stephen Nicholas; Elizabeth Maitland; Teng Fei
Journal:  Hum Vaccin Immunother       Date:  2021-01-26       Impact factor: 3.452

3.  Disease burden of hepatitis E in a rural population in China: a community-based survey.

Authors:  H Jiang; S Huang; Y Zhao; Y Wang; C Yang; J Cai; Z Wang; J Zhang; X Zhang; H Jin
Journal:  Epidemiol Infect       Date:  2017-04       Impact factor: 4.434

4.  Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study.

Authors:  Ping Chen; Yang Zheng; Yubo Cai; Pengfei Zou; Nan Li; Conggao Peng; Hainv Gao; Jimin Liu; Yongping Chen; Zhaowei Tong; Lanjuan Li
Journal:  Can J Gastroenterol Hepatol       Date:  2020-04-14

5.  Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis.

Authors:  Yang Sun; Jie Chang; Xin Liu; Chaojie Liu
Journal:  BMJ Open       Date:  2019-11-10       Impact factor: 2.692

6.  Epidemiological characteristics and trends of notifiable infectious diseases in China from 1986 to 2016.

Authors:  Yi Jiang; Xiangfeng Dou; Chenqi Yan; Li Wan; Haican Liu; Machao Li; Ruibai Wang; Guilian Li; Lili Zhao; Zhiguang Liu; Xiuqin Zhao; Kanglin Wan
Journal:  J Glob Health       Date:  2020-12       Impact factor: 4.413

7.  The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study.

Authors:  Shuo Yang; Ge Chen; Yueping Li; Guanhai Li; Yingfang Liang; Feng Zhou; Shudong Zhou; Yi Yang; Weidong Jia; Yanhui Gao; Yue Chen
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-30       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.